Share This Article:

Development and Validation of HPLC Method for Simultaneous Determination of Amlodipine, Valsartan, Hydrochlorothiazide in Dosage Form and Spiked Human Plasma

Abstract Full-Text HTML Download Download as PDF (Size:512KB) PP. 422-430
DOI: 10.4236/ajac.2012.36055    8,462 Downloads   17,265 Views   Citations

ABSTRACT

A simple, sensitive, and specific method was developed for simultaneous determination of Amlodipine besylate (AML), Valsartan (Vals) and Hydrochlorothiazide (HCT) by high performance liquid chromatography without previous separation. Satisfactory resolution was achieved using a RP-C18 chromatographic column, Phenomenex Kinetex (150 mm × 4.6 mm i.d) and a mobile phase consisting of acetonitrile-phosphate buffer (0.05 M) with pH 2.8 in the proportion of (40/60, v/v) at a flow rate 0.8 mL/min and the wavelength detection was 227 nm. The retention time for HCT, AML and VAls was 2.26, 3.16 and 11.19 min; respectively. The described method was linear over a range of 4-28 μg /ml, 5-40 μg /ml and 1-12 μg /ml for AML, Vals and HCT; respectively. The mean percent recoveries were 99.94%, 99.96% and 99.78% for AML, Vals and HCT; respectively. F-test and t-test at 95%con?dence level were used to check the intermediate precision data obtained under different experimental setups. The method could be used for analysis of combined dose tablet formulation containing AML, Vals, HCT as well as spiked human plasma.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

S. El-Gizawy, O. Abdelmageed, M. Omar, S. Deryea and A. Abdel-Megied, "Development and Validation of HPLC Method for Simultaneous Determination of Amlodipine, Valsartan, Hydrochlorothiazide in Dosage Form and Spiked Human Plasma," American Journal of Analytical Chemistry, Vol. 3 No. 6, 2012, pp. 422-430. doi: 10.4236/ajac.2012.36055.

References

[1] “The United States Pharcopoeia XXVIIII and NF XXV,” Electronic Version, American Pharmaceutical Association, Washington DC, 2007.
[2] A. C. Moffat, M. D. Osselton and B. Widdop, “Clarke’s Analysis of Drugs and Poisons,” 3rd Edition, Electronic version, Pharmaceutical Press, London, 2004.
[3] “British Pharmacopoeia, Her Majesty’s Stationary Office,” Vol. I, II, Electonic version, London, 2010.
[4] S. J. Varghese and T. K. Ravi, “Quantitative Simultaneous Determination of Amlodipine, Valsartan, and Hydrochlorothiazide in ‘Exforge HCT’ Tablets Using High-Performance Liquid Chromatograhy and High- Performance Thinlayer Chromatography,” Journal of Liquid Chromatography & Related Technologies, Vol. 34, No. 12, 2011, pp. 981-994. doi:10.1080/10826076.2011.565539
[5] K. Anandakumar and M. Jayamariappan, “Absorption Correction Method For The Simultaeous Estimation of Amlodipine Besylate,Valsartan and Hydrochlorothiazide in Bulk and in Combined Tablet Dosage Form,” Internationa Journal of Pharmacy and Pharmaceutical Sciences, Vol. 3, No. 1, 2011, pp. 23-27.
[6] K. S. Lakshmi, and S. Lakshmi, “Simultaneous Spectrophotometric Determination of Valsartan and Hydrochlorothiazide by H-Point Standard Addition Method and Partial Least Squares Regression,” Acta Pharmaceutica, Vol. 61, 2011, pp. 37-50. doi:10.2478/v10007-011-0007-5
[7] M. Stolarczyk, A. Mas-lanka, J. Krzek and J. Milczarek, “Application of Derivative Spectrophotometry for Determination of Enalapril, Hydrochlo-rothiazide and Walsartan in Complex Pharmaceutical Preparations,” Acta Poloniae Pharmaceutica, Vol. 65, No. 3, 2008, pp. 275-281.
[8] K. R. Gupta, A. D. Mahapatra, A. R. Wadodkar and S. G. Wadodkar, “Simultaneous UV Spectrophotometric Determination of Valsartan and Amlodipine in Tablet,” International Journal of ChemTech Research, Vol. 2, No. 1, 2010, pp. 551-556.
[9] S. Tatar and S. Saglik, “Comparison of UV- and Second Derivative-Spectrophotometric and LC Methods for the Determination of Valsartan in Pharmaceutical Formulation,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 30, No. 2, 2002, pp. 371-375. doi:10.1016/S0731-7085(02)00360-6
[10] E. Satana, S. Alti-nay, N. G. Goger, S. A. Ozkan and Z. Senturk, “Simultaneous Determination of Valsartan and Hydrochlorothiazide in Tablets by First-Derivative Ultraviolet Spectrophotometry and LC,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 25, No. 5-6, 2001, pp. 1009-1013. doi:10.1016/S0731-7085(01)00394-6
[11] R. Shaalan and T. S. Belal, “Simultaneous Spectro?uorimetric Determination of Amlodipine Besylate and Valsartan in Their Combined Tablets,” Drug Testing and Analysis, Vol. 2, No. 10, 2010, pp. 489-493. doi:10.1002/dta.160
[12] S. B. Wankhede, K. C. Raka, S. B. Wadkar and S. S. Chitlange, “Spectrophotometric and HPLC Methods for Simultaneous Estimation of Amlodipine Besilate, Losartan Potassium and Hydrochlorothiazide in Tablets,” Indian Journal of Pharmaceutical Sciences, Vol. 72, No. 1, 2010, pp. 136-140. doi:10.4103/0250-474X.62239
[13] D. Kul, B. Dogan-Topal, T. Kutucu, B. Uslu and S. A. Ozkan, “High-Performance Liquid Chromatographic and First Deriva-tive of the Ratio Spectrophotometric Determination of Amlodi-pine and Valsartan in Their Binary Mixtures,” Journal of AOAC International, Vol. 93, No. 3, 2010, pp. 882-890.
[14] X. Wei, G. Yang, L. Qi and Y. Chen, “Determination of Nicardipine and Amlodipine in Human Plasma Using On-Line Solid-Phase Extraction with a Monolithic Weak Cation-Exchange Column,” Talanta, Vol. 77, No. 3, 2009, pp. 1197-1202. doi:10.1016/j.talanta.2008.08.034
[15] A. V. Ramani, P. Sengupta and R. Mullangi, “Development and Validation of a Highly Sensitive and Robust LC-ESI-MS/MS Method for Simultaneous Quantitation of Simvastatin Acid, Amlodipine and Valsartan in Human Plasma: Application to a Clinical Pharmacokinetic Study,” Biomed Chromatogr, Vol. 23, No. 6, 2009, pp. 615-622. doi:10.1002/bmc.1161
[16] I. A. Alsarra, “High-Performance Liquid Chromatographic Method for Quan-titative Determination of Amlodipine in Human Plasma and Pharmaceutical Dosage Form and Its Application to Pharmaco-kinetic Studies,” Journal of Chromatographic Science, Vol. 47, No. 10, 2009, pp. 863-867.
[17] D. N. Vora and A. A. Kadav, “Development and Validation of a Simultaneous HPLC Method for Estimation of Bisoprolol Fumarate and Amlodipine Besylate from Tablets,” Indian Journal of Pharmaceutical Sciences, Vol. 70, No. 4, 2008, pp. 542-546. doi:10.4103/0250-474X.44616
[18] D. A. Shah, K. K. Bhatt, R. S. Mehta, S. L. Baldania and T. R. Gandhi, “Stability Indicating RP-HPLC Estimation of Atorvastatin Calcium and Amlodipine Besylate in Pharmaceutical Formulations,” Indian Journal of Pharmaceutical Sciences, Vol. 70, No. 6, 2008, pp. 754-760. doi:10.4103/0250-474X.49117
[19] S. Aryal, and N. Skal-ko-Basnet, “Stability of Amlodipine Besylate and Atenolol in Multi-Component Tablets of Mono-Layer and Bi-Layer Types,” Acta Pharmaceutica, Vol. 58, No. 3, 2008, pp. 299-308. doi:10.2478/v10007-008-0012-5
[20] H. Li, Y. Wang, Y. Jiang, Y. Tang, J. Wang, L. Zhao and J. Gu, “A liquid Chromatography/Tandem Mass Spectrometry Method for the Si-multaneous Quantification of Valsartan and Hydrochlorothiazide in Human Plasma,” Journal of Chromatography B, Vol. 852, No. 1-2, 2007, pp. 436-442. doi:10.1016/j.jchromb.2007.02.014
[21] G. Iriarte, N. Ferreiros, I. Ibarrondo, R. M. Alonso, M. I. Maguregi, L. Gonzalez and R. M. Jimenez, “Optimization via Experimental Design of an SPE-HPLC-UV-Fluorescence Method for the Determination of Valsartan and Its Metabolite in Human Plasma Samples,” Journal of Separation Science, Vol. 29, No. 15, 2006, pp. 2265-2283. doi:10.1002/jssc.200600093
[22] E. Francotte, A. Davatz and P. Richert, “Development and Validation of Chiral High-Performance Liquid Chromatographic Methods for the Quantitation of Valsartan and of the Tosylate of Valinebenzyl Ester,” Journal of Chromatography B: Biomedical Sciences and Applications, Vol. 686, No. 1, 1996, pp. 77-83. doi:10.1016/S0378-4347(96)00242-3
[23] D. F. Tian, X. L. Tian, T. Tian, Z. Y. Wang and F. K. Mo, “Simultaneous Determination of Valsartan and Hydrochlorothiazide in Tablets by RP-HPLC,” Indian Journal of Pharmaceutical Sciences, Vol. 70, No. 3, 2008, pp. 372-374. doi:10.4103/0250-474X.43006
[24] S. S. Chitlange, K. Bagri and D. M. Sakarkar, “Stability Indicating RP-HPLC Method for Simultaneous Estimation of Valsartan and Amlodipine in Capsule Formulation,” Asian Journal of Research in Chemistry, Vol. 7, No. 1, 2008, pp. 15-18.
[25] G. Iriarte, O. Gonzalez, N. Ferreiros, M. I. Maguregui, R. M. Alonso and R. M. Jimenez, “Validation of a Fast Liquid Chromatography-UV Method for the Analysis of Drugs Used in Combined Cardiovascular Therapy in Human Plasma,” Journal of Chromatography B, Vol. 877, No. 27, 2009, pp. 3045-3053. doi:10.1016/j.jchromb.2009.07.018
[26] N. J. Shah, B. N. Suhagia, R. R. Shah and N. M. Patel, “HPTLC Method for the Simultaneous Estimation of Valsartan and Hydrochlorothiazide in Tablet Dosage Form,” Indian Journal of Pharmaceutical Sciences, Vol. 71, No. 1, 2009,pp. 72-74. doi:10.4103/0250-474X.51967
[27] S. N. Meyyanathan and B. Suresh, “HPTLC Method for the Simultaneous Determination of Amlodipine and Benazepril in Their Formulations,” Journal of Chromatographic Science, Vol. 43, No. 2, 2005, pp. 73-75.
[28] A. O. Alnajjar, “Validation of a Capillary Electro-phoresis Method for the Simultaneous Determination of Amlo-dipine Besylate and Valsartan in Pharmaceuticals and Human Plasma,” Journal of AOAC International, Vol. 94, No. 2, 2011, pp. 498-502.
[29] S. Hillaert and W. Van den Bossche, “Si-multaneous Determination of Hydrochlorothiazide and Several Angiotensin-II-Receptor Antagonists by Capillary Electrophoresis,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 31, No. 2, 2003, pp. 329-339. doi:10.1016/S0731-7085(02)00643-X
[30] S. Hillaert and W. Van den Bossche, “Optimization and Validation of a Capillary Zone Electrophoretic Method for the Analysis of Several Angi-otensin-II-Receptor Antagonist,” Journal of Chromatography A, Vol. 979, No. 1-2, 2002, pp. 323-333. doi:10.1016/S0021-9673(02)01247-5
[31] L. Gonzalez, U. Akesolo, R. M. Jimenez and R. M. Alonso, “Application of Capillary Zone Electrophoresis to the Screening of Some Angi-otensin II Receptor Antagonists,” Electrophoresis, Vol. 23, No. 2, 2002, pp. 223-229. doi:10.1002/1522-2683(200202)23:2<223::AID-ELPS223>3.0.CO;2-T
[32] J. Yan, W. Wang, L. Chen and S. Chen, “Electrochemical Behavior of Valsartan and Its Determination in Capsules,” Colloids Surf B Biointerfaces, Vol. 67, No. 2, 2008, pp. 205-209. doi:10.1016/j.colsurfb.2008.08.015
[33] A. A. Gazy, “Determination of Amlodipine Besylate by Adsorptive Square-Wave Anodic Stripping Voltammetry on Glassy Carbon Electrode in Tablets and Biological Fluid,” Talanta, Vol. 62, No. 3, 2004, pp. 575-582. doi:10.1016/j.talanta.2003.08.025
[34] G. Altiokka, D. Do-grukol-Ak, M. Tuncel and H. Y. Aboul-Enein, “Determination of Amlodipine in Pharmaceutical Formulations by Differen-tial-Pulse Voltammetry with a Glassy Carbon Electrode,” Archiv der Pharmazie (Weinheim), Vol. 335, No. 2, 2002, pp. 104-108. doi:10.1002/1521-4184(200203)335:2/3<104::AID-ARDP104>3.0.CO;2-Q
[35] ICH Harmonized Tripartie Guidline Q2B (R1), “Validation of Analytical Proceudures: Text and Methodology,” Incorporated in November 2005. http://www.ich.org
[36] ICH Harmonized Tripartie Guidline Q2A, “Text on Validation of Analytical Procedures,” Incorporated in November 2005. http://www.ich.org
[37] K. Rao, N. Jena and M. Rao, “Development and Validation of a Specific Stability Indicating High Performance Liquid Chromatographic Method for Valsartan,” Journal of Young Pharmacists, Vol. 2, No. 2, 2010, pp. 183-189. doi:10.4103/0975-1483.63166
[38] A. Zarghi, S. M. Foroutan, A. Shafaati and A. Khoddam, “Validated HPLC Method for Determination of Amlodipine in Human Plasma and Its Application to Pharmacokinetic Studies,” Farmaco, Vol. 60, No. 9, 2005, pp. 789-792. doi:10.1016/j.farmac.2005.06.012
[39] K. B. Alton, D. Desrivieres and J. E. Patrick, “High-Performance Liquid Chromatographic Assay for Hydrochlorothiazide in Human Urine,” Journal of Chromatography, Vol. 374, No. 1, 1986, pp. 103-110.

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.